Smart inhaler delivers results for kids with asthma
Smart inhaler delivers results for kids with
asthma
Media
Release
University of Auckland and Cure Kids NZ
20 January 2014
Please note change to embargo
EMBARGOED until 1am Wednesday
21st January for live broadcast and NZ print
outlets.
All online postings of this
story are embargoed until 1pm on 21 January
2015
Smart inhaler delivers results for kids with asthma
A new smart asthma inhaler with an audio-visual function has dramatically improved child and adolescent use of preventative asthma medication.
The users also experienced significant improvements to their symptoms, well-being and quality of life and needed their reliever medication less frequently.
The University of Auckland study, funded by Cure Kids and the Health Research Council, showed a significant improvement in night time awakening, coughing and wheezing.
Professor Ed Mitchell, Cure Kids Chair of Child Health Research and supervisor of the study’s lead author, Amy Chan says he is “absolutely staggered by the size of the effect. To see the improvement in the lives of these children is astounding.”
The participants also reported taking part in more sports and family activities. Parents reported feeling less frightened by their child’s asthma.
New Zealand has the second highest rates of asthma in the world and one in four Kiwi children experiences asthma symptoms. Despite this, regular adherence to asthma medication is poor.
New Zealand digital health company Nexus6 Ltd created a new Smartinhaler device called the SmartTrack, which was used in the study. The device has 14 different ringtones, which are cycled so users don’t get reminder fatigue. The SmartTrack reminder is only triggered when a dose is missed.
The results were published this month in The Lancet Respiratory Medical Journal.
To the researchers’ knowledge, this is the largest study in the world to investigate the effects of an inhaler device with audio-visual reminder function on asthma adherence and outcomes in children and adolescents.
It is also the first to show significant benefits in asthma outcomes and quality of life. The results are expected to gain international interest.
The randomized controlled trial recruited 220 children between the ages of six and 15 who presented to emergency departments with asthma symptoms.
The study was random with half of the participants receiving a SmartTrack device for use with their preventative or ‘orange’ inhaler that had the audiovisual elements turned on, and the other half receiving the same device with the audiovisual elements turned off.
Participants were followed up every 2 months for six months and general asthma control was checked.
Key findings from the study were:
o Medication adherence rate
for the patient group given the audiovisual enabled
SmartTrack inhaler were 84 percent compared to 30 percent
for the control group. This equals a 180% increase in
medication adherence.
o The use of emergency medication
or the ‘blue’ inhaler was significantly reduced. The
median percentage days on which a reliever was used in the
intervention group was 9.5 percent compared to 17.4 percent
in the control group. This equals a 45 percent reduction in
rescue medication use.
o Symptoms, well-being and
quality of life for the children was significantly
improved.
o
Clinical pharmacist, Amy Chan, a doctoral
student with the University of Auckland, is the lead author
on the paper.
“We know one of the key reasons for children not taking their medication is parent and patient forgetfulness. The Smartinhaler reminder system is now clinically proven to be a real solution to the problem,” she says.
“What we’ve been able to establish for the first time with this study is that the ringtone Smartinhaler significantly improves adherence to preventative medication, which results in improved quality of life for children with asthma. It’s hugely exciting,” says Chan.
Children in the study were also given a Smartinhaler tracker for their rescue or ‘blue’ inhaler to measure the amount of rescue medication they used. The device was able to objectively count date and time of rescue medication use. This provided a good indication of asthma being out of control.
When symptoms worsened participants used their rescue reliever inhaler (blue inhaler), which is also known as a rescue medication because it provides immediate relief. Recent studies have shown that overuse of the blue inhaler is a predictor of worsening asthma and general morbidity.
The study found that use of the rescue medication was significantly reduced in the group using the Nexus6 Smartinhaler reminder device.
ENDS
Notes to Editors
ABOUT THE SMART TRACK DEVICE AND NEXUS6 SMARTINHALER DEVICE
New Zealand digital health company Nexus6 Ltd created the SmartInhaler device used in the study. This device, called the SmartTrack, has 14 different ringtones, which are cycled so users don’t get reminder fatigue.
Users were asked what time of morning and evening they wanted to be reminded and the device was customized to their preferences. The reminder only rings if the medication hasn’t been taken.
The display on the side of the SmartInhaler shows the last time the medication was taken. Chan says the device also allowed the researchers to obtain accurate electronic data, as the device records the exact date and time the medication is used.
Nexus6 had no role in any aspect of the trial beyond designing and supplying the Smartinhaler devices and reporting software at the outset of the study. The device has US FDA, CE, TGA and NZ approvals and Nexus6 is exploring opportunities for launching the product in the market to Doctors and patients.
CEO Garth Sutherland founded Nexus6 Ltd in 2001 having had asthma all his life. He wanted a solution for automatically tracking his asthma medication use to improve his asthma management. Garth graduated with a Masters of Science in Physics from the University of Waikato with First-Class Honours. He has spent the last 20 years working for some of the world's top technology companies in Europe, North America and Australasia including Microsoft Corporation and the Gallagher Group.